GlycoMimetics (GLYC) Reports Q4 Loss of $0.47/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
GlycoMimetics Reports Fourth Quarter and Year-End 2015 Results
February 29, 2016 5:00 PM ESTROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the fourth quarter and year ended December 31, 2015. As of December 31, 2015, GlycoMimetics had cash and cash equivalents of $46.8 million, which reflects a $20.0 million non-refundable milestone payment received from Pfizer Inc. in August 2015 under the terms of the parties collaboration agreement for development of rivipansel (previously known as GMI-1070).
For the quarter ended December 31, 2015, GlycoMimetics reported total revenues of $35,000. GlycoMimetics did not recognize any revenues in the quarter ended December 31, 2014. For the year ended December 31, 2015, total revenues were $20.1 million compared to $15.0 million in... More
